Cost of Goods Sold (Annual)

Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.

Xeris Biopharma Holdings, Inc. (XERS) had Cost of Goods Sold of $28.64M for the most recently reported fiscal year, ending 2023-12-31.

Quarterly Annual

Figures for fiscal year ending 2023-12-31

Income Statement Financials
Revenue	$163.91M
Net Income	$-62.26M
Cost of Goods Sold	$28.64M
Gross Profit	$135.27M
Operating Expenses	$207.92M
Operating Income	$-44.01M
Non-Operating Income/Expense	$-19.49M
Pre-Tax Income	$-63.50M
Normalized Pre-Tax Income	$-63.50M
Income after Taxes	$-62.26M
Income from Continuous Operations	$-62.26M
Consolidated Net Income/Loss	$-62.26M
Normalized Income after Taxes	$-62.26M
EBIT	$-44.01M
EBITDA	$-28.64M
Weighted-Average Shares Outstanding (Basic)	137.68M
Weighted-Average Shares Outstanding (Diluted)	137.68M
Earnings per Share (EPS) (Basic)	$-0.45
Earnings per Share (EPS) (Diluted)	$-0.45
Balance Sheet Financials
Current Assets	$156.26M
Property, Plant, and Equipment	$5.97M
Long-Term Assets	$166.34M
Total Assets	$322.60M
Current Liabilities	$95.19M
Long-Term Debt	$190.93M
Long-Term Liabilities	$234.19M
Total Liabilities	$329.38M
Common Equity	$-6.78M
Tangible Shareholders Equity	$-139.41M
Shareholders Equity	$-6.78M
Common Shares Outstanding	138.13M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-47.02M
Cash Flow from Investing Activities	$-6.00M
Cash Flow from Financial Activities	$-1.61M
Beginning Cash	$126.31M
End Cash	$71.67M
Increase/Decrease in Cash	$-54.64M
Stock-Based Compensation	$10.72M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.64
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.04
Debt to Equity Ratio	-28.15
Gross Margin	82.52%
Operating Margin	-26.85%
EBIT Margin	-26.85%
EBITDA Margin	-17.48%
Pre-Tax Profit Margin	-38.74%
Profit Margin	-37.98%
Free Cash Flow	$-49.29M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.51
Inventory Turnover	0.74
Receiveable Turnover	4.18
Days Sales in Receivables	87.28
Return on Equity	917.94%
Return on Tangible Equity	44.66%
Return on Assets	-19.30%
Return on Investments	-33.81%
Book Value Per Share	$-0.05
Free Cash Flow per Share	$-0.36
Operating Cash Flow per Share	$-0.34

Data from Zacks Investment Research, Inc.